Measuring indirect effects of rotavirus vaccine in low income countries

Vaccine

Volumn 34, Issue 37, 2016, Pages 4351-4353

  Bennett, Aisleen ^a,b   Bar Zeev, Naor ^a,b   Cunliffe, Nigel A ^a,b  

^a MALAWI LIVERPOOL WELLCOME TRUST CLINICAL RESEARCH PROGRAMME   (Malawi)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Gastroenteritis; Herd effects; Rotavirus; Vaccine

Indexed keywords

CHOLERA VACCINE; PLACEBO; ROTAVIRUS VACCINE;

CHOLERA; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; HERD IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW INCOME COUNTRY; MALNUTRITION; MORTALITY; NONHUMAN; NOTE; POPULATION STRUCTURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ROTAVIRUS INFECTION; VACCINATION; VIRAL GASTROENTERITIS; VIRUS SHEDDING; VIRUS TRANSMISSION; COST BENEFIT ANALYSIS; COST OF ILLNESS; DEVELOPING COUNTRY; GASTROENTERITIS; ROTAVIRUS INFECTIONS; VIROLOGY;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; GASTROENTERITIS; HUMANS; IMMUNITY, HERD; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES;

EID: 84990929757     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.07.001     Document Type: Note

References (32)

1. [1] Tate, J.E., Burton, A.H., Boschi-Pinto, C., Steele, A.D., Duque, J., Parashar, U.D., 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lan Infect Dis 12 (2012), 136–141.
2. [2] Lopman, B.A., Payne, D.C., Tate, J.E., Patel, M.M., Cortese, M.M., Parashar, U.D., Post-licensure experience with rotavirus vaccination in high and middle income countries; 2006 to 2011. Curr Opin Virol 2 (2012), 434–442.
3. [3] Madhi, S.A., Cunliffe, N.A., Steele, D., Witte, D., Kirsten, M., Louw, C., et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New Engl J Med 362 (2010), 289–298.
4. [4] Zaman, K., Dang, D.A., Victor, J.C., Shin, S., Yunus, M., Dallas, M.J., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 376 (2010), 615–623.
5. [5] Bar-Zeev, N., Kapanda, L., Tate, J.E., Jere, K.C., Iturriza-Gomara, M., Nakagomi, O., et al. Effectiveness of a monovalent rotavirus vaccine in infants in Malawi after programmatic roll-out: an observational and case-control study. Lan Infect Dis 15 (2015), 422–428.
6. [6] Ngabo, F., Tate, J.E., Gatera, M., Rugambwa, C., Donnen, P., Lepage, P., et al. Effect of pentavalent rotavirus vaccine introduction on hospital admissions for diarrhoea and rotavirus in children in Rwanda: a time-series analysis. Lan Global Health 4 (2016), e129–e136.
7. [7] Halloran, M.E., Haber, M., Longini, I.M. Jr., Struchiner, C.J., Direct and indirect effects in vaccine efficacy and effectiveness. Am J Epidemiol 133 (1991), 323–331.
8. [8] Halloran, H.E., Longini, I.M., Struchiner, C.J., Design and analysis of vaccine studies. 1st ed., 2010, Springer, New York.
9. [9] Paul, Y., Herd immunity and herd protection. Vaccine 22 (2004), 301–302.
10. [10] Vanderweele, T.J., Tchetgen Tchetgen, E.J., Halloran, M.E., Components of the indirect effect in vaccine trials: identification of contagion and infectiousness effects. Epidemiology (Cambridge, Mass) 23 (2012), 751–761.
11. [11] Paulke-Korinek, M., Kundi, M., Rendi-Wagner, P., de Martin, A., Eder, G., Schmidle-Loss, B., et al. Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria. Vaccine 29 (2011), 2791–2796.
12. [12] Standaert, B., Strens, D., Alwan, A., Raes, M., Medium- to long-term impact of rotavirus vaccination on hospital care in Belgium: a 7-year follow-up of the rotavirus Belgium impact study (RotaBIS). Infect Dis Therapy 5 (2016), 31–44.
13. [13] Atchison, C.J., Stowe, J., Andrews, N., Collins, S., Allen, D.J., Nawaz, S., et al. Rapid declines in age group-specific rotavirus infection and acute gastroenteritis among vaccinated and unvaccinated individuals within 1 year of rotavirus vaccine introduction in England and Wales. J Infect Dis 213 (2016), 243–249.
14. [14] Payne, D.C., Staat, M.A., Edwards, K.M., Szilagyi, P.G., Weinberg, G.A., Hall, C.B., et al. Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US counties, 2006–2009. Clin Infect Dis 53 (2011), 245–253.
15. [15] Yen, C., Armero Guardado, J.A., Alberto, P., Rodriguez Araujo, D.S., Mena, C., Cuellar, E., et al. Decline in rotavirus hospitalizations and health care visits for childhood diarrhea following rotavirus vaccination in El Salvador. Ped Infect Dis J 30 (2011), S6–S10.
16. [16] Clarke, M.F., Davidson, G.P., Gold, M.S., Marshall, H.S., Direct and indirect impact on rotavirus positive and all-cause gastroenteritis hospitalisations in South Australian children following the introduction of rotavirus vaccination. Vaccine 29 (2011), 4663–4667.
17. [17] Curns, A.T., Steiner, C.A., Barrett, M., Hunter, K., Wilson, E., Parashar, U.D., Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states. J Infect Dis 201 (2010), 1617–1624.
18. [18] Prelog, M., Gorth, P., Zwazl, I., Kleines, M., Streng, A., Zlamy, M., et al. Universal mass vaccination against rotavirus: indirect effects on rotavirus infections in neonates and unvaccinated young infants not eligible for vaccination. J Infect Dis, 2016 pii: jiw186, [Epub ahead of print].
19. [19] Lopman, B.A., Curns, A.T., Yen, C., Parashar, U.D., Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J Infect Dis 204 (2011), 980–986.
20. [20] Pollard, S.L., Malpica-Llanos, T., Friberg, I.K., Fischer-Walker, C., Ashraf, S., Walker, N., Estimating the herd immunity effect of rotavirus vaccine. Vaccine 33 (2015), 3795–3800.
21. [21] Mast, T.C., Wang, F.T., Su, S., Seeger, J.D., Evidence of herd immunity and sustained impact of rotavirus vaccination on the reduction of rotavirus-related medical encounters among infants from 2006 through 2011 in the United States. Ped Infect Dis J 34 (2015), 615–620.
22. [22] Hsieh, Y.C., Wu, F.T., Hsiung, C.A., Wu, H.S., Chang, K.Y., Huang, Y.C., Comparison of virus shedding after lived attenuated and pentavalent reassortant rotavirus vaccine. Vaccine 32 (2014), 1199–1204.
23. [23] Payne, D.C., Edwards, K.M., Bowen, M.D., Keckley, E., Peters, J., Esona, M.D., et al. Sibling transmission of vaccine-derived rotavirus (RotaTeq) associated with rotavirus gastroenteritis. Pediatrics 125 (2010), e438–e441.
24. [24] Rivera, L., Pena, L.M., Stainier, I., Gillard, P., Cheuvart, B., Smolenov, I., et al. Horizontal transmission of a human rotavirus vaccine strain–a randomized, placebo-controlled study in twins. Vaccine 29 (2011), 9508–9513.
25. [25] Lopman, B., Vicuna, Y., Salazar, F., Broncano, N., Esona, M.D., Sandoval, C., et al. Household transmission of rotavirus in a community with rotavirus vaccination in Quininde, Ecuador. PloS One, 8, 2013, e67763.
26. [26] Koopman, J.S., Monto, A.S., Longini, I.M. Jr., The Tecumseh Study. XVI: family and community sources of rotavirus infection. Am J Epidemiol 130 (1989), 760–768.
27. [27] Kang, G., Iturriza-Gomara, M., Wheeler, J.G., Crystal, P., Monica, B., Ramani, S., et al. Quantitation of group A rotavirus by real-time reverse-transcription-polymerase chain reaction: correlation with clinical severity in children in South India. J Med Virol 73 (2004), 118–122.
28. [28] Jeuland, M., Cook, J., Poulos, C., Clemens, J., Whittington, D., Cost-effectiveness of new-generation oral cholera vaccines: a multisite analysis. Value In Health: J Int Soc Pharmacoecon Outcomes Res 12 (2009), 899–908.
29. [29] Ali, M., Emch, M., von Seidlein, L., Yunus, M., Sack, D.A., Rao, M., et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 366 (2005), 44–49.
30. [30] Clemens, J., Shin, S., Ali, M., New approaches to the assessment of vaccine herd protection in clinical trials. Lan Infect Dis 11 (2011), 482–487.
31. [31] Piszczek, J., Partlow, E., Stepped-wedge trial design to evaluate Ebola treatments. Lan Infect Dis 15 (2015), 762–763.
32. [32] Halloran, M.E., The minicommunity design to assess indirect effects of vaccination. Epidemiol Meth 1 (2012), 83–105.